With increasing awareness of genetic abnormalities and the aging of patients with structural cardiac disease, particularly those who have had cardiac surgery, primary ventricular tachycardia is being recognized more frequently in children and adolescents and is becoming a larger management issue. The distinction of primary versus secondary is based on whether ventricular tachycardia is the inciting arrhythmia or the end result of a prolonged ischemic event, such as prolonged bradycardia with resultant ventricular tachycardia. This article discusses only primary ventricular tachycardia. The incidence clearly increases with age after cardiac surgery, particularly in specific cardiac abnormalities, such as tetralogy of Fallot post repair, transposition of the great arteries, post atrial switch operation, and hypertrophic obstructive cardiomyopathy. In addition, as genetic abnormalities are becoming better appreciated, conditions such as long QT syndrome, arrhythmogenic right ventricular cardiomyopathy, and Brugada syndrome, with their risk for ventricular tachycardia and fibrillation, are being seen increasingly in the pediatric population. Long-term treatment of ventricular tachycardia includes drug therapy, implantable device therapy, invasive ablation therapy, and combinations of these modalities. To choose the appropriate therapy, the clinician must consider the arrhythmia's effect on the patient's hemodynamic status and the potential for sudden cardiac death.